An uphill battle downstream of RAF

Journal of Clinical Oncology

Volumn 29, Issue 17, 2011, Pages 2298-2300

  Collisson, Eric A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AS 703026; B RAF KINASE; GSK 1120212; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; RAF PROTEIN; RAS PROTEIN; SELUMETINIB; SORAFENIB; UNCLASSIFIED DRUG;

ALCOHOL LIVER CIRRHOSIS; BILE DUCT CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; DRUG MECHANISM; EDITORIAL; EYE TOXICITY; GENE MUTATION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; PHASE 2 CLINICAL TRIAL (TOPIC); PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BENZIMIDAZOLES; BILIARY TRACT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 79959246003     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.9316     Document Type: Editorial

References (15)

1. Hezel AF, Deshpande V, Zhu AX: Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 28:3531-3540, 2010
2. O'Neil BH, Goff LW, Kauh JS, et al: Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 29:2350-2356, 2011
3. Bekaii-Saab T, Phelps MA, Li X, et al: Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29:2357-2363, 2011
4. McCormick F: Success and failure on the ras pathway. Cancer Biol Ther 6:1654-1659, 2007
5. Tannapfel A, Sommerer F, Benicke M, et al: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52:706-712, 2003 (Pubitemid 36528874)
6. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300, 2006 (Pubitemid 46630787)
7. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
8. Boyault S, Rickman DS, de Reyniès A, et al: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42-52, 2007 (Pubitemid 46144363)
9. Infante JR, Fecher LA, Nallapareddy S, et al: Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 28:204s, 2010 (suppl; abstr 2503)
10. Delord J, Houede N, Awada A, et al: First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors. J Clin Oncol 28:205s, 2010 (suppl; abstr 2504)
11. Sebolt-Leopold JS: Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res 14:3651-3656, 2008
12. Bollag G, Hirth P, Tsai J, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599, 2010
13. Dry JR, Pavey S, Pratilas CA, et al: Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 70:2264-2273, 2010
14. Garon EB, Finn RS, Hosmer W, et al: Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther 9:1985-1994, 2010
15. Singh A, Greninger P, Rhodes D, et al: A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15:489-500, 2009